Financial Performance - The company's basic earnings per share (EPS) for Q1 2025 is 0.0829 yuan, a decrease of 42.98% compared to Q1 2024's EPS of 0.1454 yuan [1] - Net profit for Q1 2025 is 0.06 billion yuan, down 40% from 0.1 billion yuan in Q1 2024 [1] - Operating revenue for Q1 2025 is 1.04 billion yuan, an increase of 15.56% from 0.9 billion yuan in Q1 2024 [1] - The return on equity (ROE) for Q1 2025 is 0.74%, a decline of 43.51% from 1.31% in Q1 2024 [1] - The company's net assets per share increased to 11.3 yuan, up 1.16% from 11.17 yuan in Q1 2024 [1] Shareholder Structure - The top ten unrestricted shareholders hold a total of 5.3909 million shares, accounting for 29.27% of the circulating shares, with a change of 326,900 shares from the previous period [1] - Major shareholders include Mi Ying with 3.3923 million shares (18.42%), and Chen Feng with 0.4055 million shares (2.20%), who increased their holdings by 89,500 shares [2] - New entrants among the top shareholders include Zhang Mingsheng and Ge Yuejin, holding 0.3427 million shares (1.86%) and 0.2694 million shares (1.46%) respectively [2] - Chen Xuelan, Lin Zhifeng, and others have exited the top ten shareholders list [2] Dividend Policy - The company has decided not to distribute or transfer any dividends this time [3]
五洲医疗:2025一季报净利润0.06亿 同比下降40%